References
- Adams, C. M., Anderson, K., Artman, G., Bizec, J.-C., Cepeda, R., Elliott, J., Fassbender, E., Ghosh, M., Hanks, S., Hardegger, L. A., Hosagrahara, V. P., Jaffee, B., Jendza, K., Ji, N., Johnson, L., Lee, W., Liu, D., Liu, F., Long, D., … Zhang, Y. (2018). The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. Journal of Medicinal Chemistry, 61(4), 1622–1635. https://doi.org/https://doi.org/10.1021/acs.jmedchem.7b01731
- Amaya, H., Tanigawa, N., Lu, C., Matsumura, M., Shimomatsuya, T., Horiuchi, T., & Muraoka, R. (1997). Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Letters, 119(2), 227–235. https://doi.org/https://doi.org/10.1016/S0304-3835(97)00280-2 https://doi.org/https://doi.org/10.1016/S0304-3835(97)00280-2
- Anantram, A., Kundaikar, H., Degani, M., & Prabhu, A. (2018). Molecular dynamic simulations on an inhibitor of anti-apoptotic Bcl-2 proteins for insights into its interaction mechanism for anti-cancer activity. Journal of Biomolecular Structure and Dynamics, 37(12), 3109–3121. https://doi.org/https://doi.org/10.1080/07391102.2018.1508371
- Backes, A. C., Zech, B., Felber, B., Klebl, B., & Müller, G. (2008). Small-molecule inhibitors binding to protein kinase. Part II: The novel pharmacophore approach of type II and type III inhibition. Expert Opinion on Drug Discovery, 3(12), 1427–1449. . https://doi.org/https://doi.org/10.1517/17460440802580106
- Bogoyevitch, M. A., Barr, R. K., & Ketterman, A. J. (2005). Peptide inhibitors of protein kinases-discovery, characterisation and use. Biochimica et Biophysica Acta, 1754(1-2), 79–99. https://doi.org/https://doi.org/10.1016/j.bbapap.2005.07.025
- Bold, G., Schnell, C., Furet, P., McSheehy, P., Brüggen, J., Mestan, J., Manley, P. W., Drückes, P., Burglin, M., Dürler, U., Loretan, J., Reuter, R., Wartmann, M., Theuer, A., Bauer-Probst, B., Martiny-Baron, G., Allegrini, P., Goepfert, A., Wood, J., & Littlewood-Evans, A. (2016). A novel potent oral series of VEGFR2 inhibitors abrogate tumor growth by inhibiting angiogenesis. Journal of Medicinal Chemistry, 59(1), 132–146.https://doi.org/https://doi.org/10.1021/acs.jmedchem.5b01582
- Cao, Z.-X., Zheng, R.-L., Lin, H.-J., Luo, S.-D., Zhou, Y., Xu, Y.-Z., Zeng, X.-X., Wang, Z., Zhou, L.-N., Mao, Y.-Q., Yang, L., Wei, Y.-Q., Yu, L.-T., Yang, S.-Y., & Zhao, Y.-L. (2011). SKLB610: A novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. Cellular Physiology and Biochemistry : international Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 27(5), 565–574.https://doi.org/https://doi.org/10.1159/000329978
- Christinger, H. W., Fuh, G., de Vos, A. M., & Wiesmann, C. (2004). The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. The Journal of Biological Chemistry, 279(11), 10382–10388.https://doi.org/https://doi.org/10.1074/jbc.M313237200
- Chu, J. S., Ge, F. J., Zhang, B., Wang, Y., Silvestris, N., Liu, L. J., Zhao, C. H., Lin, L., Brunetti, A. E., Fu, Y. L., Wang, J., Paradiso, A., & Xu, J. M. (2013). Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research : Cr, 32(1), 16.https://doi.org/https://doi.org/10.1186/1756-9966-32-16
- Cowey, C. L. (2013). Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma. Drug Design. Drug Des Devel Ther, 7, 519–527.https://doi.org/https://doi.org/10.2147/DDDT.S31442
- Dai, Y., Hartandi, K., Ji, Z., Ahmed, A. A., Albert, D. H., Bauch, J. L., Bouska, J. J., Bousquet, P. F., Cunha, G. A., Glaser, K. B., Harris, C. M., Hickman, D., Guo, J., Li, J., Marcotte, P. A., Marsh, K. C., Moskey, M. D., Martin, R. L., Olson, A. M., … Michaelides, M. R. (2007). Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. Journal of Medicinal Chemistry, 50(7), 1584–1597. https://doi.org/https://doi.org/10.1021/jm061280h
- Dixelius, J., Mäkinen, T., Wirzenius, M., Karkkainen, M. J., Wernstedt, C., Alitalo, K., & Claesson-Welsh, L. (2003). Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. Journal of Biological Chemistry, 278(42), 40973–40979. https://doi.org/https://doi.org/10.1074/jbc.M304499200
- Fang, P., Zhang, L., Zhang, X., Yu, J., Sun, J., Jiang, Q-a., Zha, M., Nesterova, A. P., & Cao, H. (2019). Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance—A Multicenter Randomized. Scientific Reports, 9(1), 1–8. https://doi.org/https://doi.org/10.1038/s41598-019-50350-6
- Fuh, G., Li, B., Crowley, C., Cunningham, B., & Wells, J. A. (1998). Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. Journal of Biological Chemistry, 273(18), 11197–11204. https://doi.org/https://doi.org/10.1074/jbc.273.18.11197
- Fujio, Y., & Walsh, K. (1999). Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. Journal of Biological Chemistry, 274(23), 16349–16354. https://doi.org/https://doi.org/10.1074/jbc.274.23.16349
- Garton, A. J., Crew, A. P. A., Franklin, M., Cooke, A. R., Wynne, G. M., Castaldo, L., Kahler, J., Winski, S. L., Franks, A., Brown, E. N., Bittner, M. A., Keily, J. F., Briner, P., Hidden, C., Srebernak, M. C., Pirrit, C., O'Connor, M., Chan, A., Vulevic, B., … Gibson, N. W. (2006). OSI-930: A novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Research, 66(2), 1015–1024.https://doi.org/https://doi.org/10.1158/0008-5472.CAN-05-2873
- Ghorab, M. M., Alsaid, M. S., Soliman, A. M., & Ragab, F. A. (2017). VEGFR-2 inhibitors and apoptosis inducers: Synthesis and molecular design of new benzo[g]quinazolin bearing benzenesulfonamide moiety. Journal of Enzyme Inhibition and Medicinal Chemistry, 32(1), 893–907.https://doi.org/https://doi.org/10.1080/14756366.2017.1334650
- Ghosh, S., Sullivan, C. A. W., Zerkowski, M. P., Molinaro, A. M., Rimm, D. L., Camp, R. L., & Chung, G. G. (2008). High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Human Pathology, 39(12), 1835–1843.https://doi.org/https://doi.org/10.1016/j.humpath.2008.06.004
- Goel, G. (2018). Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug? Cancer Management and Research, 10, 425–437. https://doi.org/https://doi.org/10.2147/CMAR.S88825
- Halin, C., Fahrngruber, H., Meingassner, J. G., Bold, G., Littlewood-Evans, A., Stuetz, A., & Detmar, M. (2008). Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol, 173(1), 265–277.https://doi.org/https://doi.org/10.2353/ajpath.2008.071074
- Hariz, M. F. (2019). Uji sitotoksik, toksisitas dan prediksi sifat fisikokimia senyawa isoliquiritigenin dan oxyresveratrol terhadap Reseptor B-cell lymphoma 2 (4) dan Vascular Endothelial Growth Factor Receptor-2 (2RL5) sebagai terapi Kanker Serviks secara in silico. Universitas Islam Negeri Maulana Malik Ibrahim.
- Huang, L., Huang, Z., Bai, Z., Xie, R., Sun, L., & Lin, K. (2012). Development and strategies of VEGFR-2/KDR inhibitors. Future Medicinal Chemistry, 4(14), 1839–1852.https://doi.org/https://doi.org/10.4155/fmc.12.121.
- Hui, R., Pearson, A., Cortes, J., Campbell, C., Poirot, C., Azim, H. A., Fumagalli, D., Lambertini, M., Daly, F., Arahmani, A., Perez-Garcia, J., Aftimos, P., Bedard, P. L., Xuereb, L., Scheepers, E. D., Vicente, M., Goulioti, T., Loibl, S., Loi, S., … Curigliano, G. (2020). Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study . Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 26(2), 354–363.https://doi.org/https://doi.org/10.1158/1078-0432.CCR-19-1164
- Huse, M., & Kuriyan, J. (2002). The conformational plasticity of protein kinases. Cell, 109(3), 275–282.https://doi.org/https://doi.org/10.1016/s0092-8674(02)00741-9
- Kawakami, J. K., Martinez, Y., Sasaki, B., Harris, M., Kurata, W. E., & Lau, A. F. (2011). Investigation of a novel molecular descriptor for the lead optimization of 4-aminoquinazolines as vascular endothelial growth factor receptor-2 inhibitors: Application for quantitative structure-activity relationship analysis in lead optimization. Bioorganic & Medicinal Chemistry Letters, 21(5), 1371–1375. https://doi.org/https://doi.org/10.1016/j.bmcl.2011.01.037
- Kendall, R. L., Rutledge, R. Z., Mao, X., Tebben, A. J., Hungate, R. W., & Thomas, K. A. (1999). Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues. Journal of Biological Chemistry, 274(10), 6453–6460. https://doi.org/https://doi.org/10.1074/jbc.274.10.6453
- Kirkland, L. O., & McInnes, C. (2009). Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. Biochemical Pharmacology, 77(10), 1561–1571.https://doi.org/https://doi.org/10.1016/j.bcp.2008.12.022
- Koch, S., Tugues, S., Li, X., Gualandi, L., & Claesson-Welsh, L. (2011). Signal transduction by vascular endothelial growth factor receptors. Biochemical Journal, 437(2), 169–183. https://doi.org/https://doi.org/10.1042/BJ20110301
- Kotha, S., & Kulkarni, V. M. (2020). An In-Silico approach: Identification of PPAR-γ agonists from Seaweeds for the management of Alzheimer’s Disease. Journal of Biomolecular Structure & Dynamics, 1-20.https://doi.org/https://doi.org/10.1080/07391102.2020.1747543
- Lamalice, L., Houle, F., Jourdan, G., & Huot, J. (2004). Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene, 23(2), 434–410. https://doi.org/https://doi.org/10.1038/sj.onc.1207034
- Le Boeuf, F., Houle, F., & Huot, J. (2004). Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. Journal of Biological Chemistry, 279(37), 39175–39185. https://doi.org/https://doi.org/10.1074/jbc.M405493200
- Liu, Y., & Gray, N. S. (2006). Rational design of inhibitors that bind to inactive kinase conformations. Nature Chemical Biology, 2(7), 358–364. https://doi.org/https://doi.org/10.1038/nchembio799
- Liu, Y., He, Y., Yang, F., Cong, X., Wang, J., Peng, S., Gao, D., Wang, W., Lan, L., Ying, X., Liu, M., Chen, Y., & Yi, Z. (2017). A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling. Science China. Life Sciences, 60(2), 202–214.https://doi.org/https://doi.org/10.1007/s11427-016-0369-6
- Matsumoto, T., Bohman, S., Dixelius, J., Berge, T., Dimberg, A., Magnusson, P., Wang, L., Wikner, C., Qi, J. H., Wernstedt, C., Wu, J., Bruheim, S., Mugishima, H., Mukhopadhyay, D., Spurkland, A., & Claesson-Welsh, L. (2005). VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. The EMBO Journal, 24(13), 2342–2353. https://doi.org/https://doi.org/10.1038/sj.emboj.7600709
- McMullen, M. E., (2005). Activation of P38 Has Opposing Effects on the Proliferation and Migration of Endothelial Cells. The Journal of Biological Chemistry, 280(22), 20995–21003. Bryant, P. W., Glembotski, C. C., Vincent, P. A., & Pumiglia, K. M.https://doi.org/https://doi.org/10.1074/jbc.M407060200
- Modi, S. J., & Kulkarni, V. M. (2019). Vascular endothelial growth factor receptor (VEGFR-2)/KDR inhibitors: Medicinal chemistry perspective. Medicine in Drug Discovery, 2, 100009. https://doi.org/https://doi.org/10.1016/j.medidd.2019.100009
- Modi, S. J., & Kulkarni, V. M. (2020). Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma. European Journal of Medicinal Chemistry, 207, 112851
- Nakamura, K., Yamamoto, A., Kamishohara, M., Takahashi, K., Taguchi, E., Miura, T., Kubo, K., Shibuya, M., & Isoe, T. (2004). KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Molecular Cancer Therapeutics, 3(12), 1639–1649.
- Ohno, H., Uemura, Y., Murooka, H., Takanashi, H., Tokieda, T., Ohzeki, Y., Kubo, K., & Serizawa, I. (2008). The orally‐active and selective c‐Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen‐induced arthritis mouse model. European Journal of Immunology, 38(1), 283–291.200737199 https://doi.org/https://doi.org/10.1002/eji
- Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006). VEGF receptor signalling - in control of vascular function. Nature Reviews Molecular Cell Biology, 7(5), 359–371.https://doi.org/https://doi.org/10.1038/nrm1911
- Paragliola, R. M., Corsello, A., Del Gatto, V., Papi, G., Pontecorvi, A., & Corsello, S. M. (2020). Lenvatinib for thyroid cancer treatment: Discovery, pre-clinical development and clinical application. Expert Opinion on Drug Discovery, 15(1), 11–26. https://doi.org/https://doi.org/10.1080/17460441.2020.1674280
- Parast, C. V., Mroczkowski, B., Pinko, C., Misialek, S., Khambatta, G., & Appelt, K. (1998). Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis. Biochemistry, 37(47), 16788–16801.https://doi.org/https://doi.org/10.1021/bi981291f
- Patnaik, A., Swanson, K. D., Csizmadia, E., Solanki, A., Landon-Brace, N., Gehring, M. P., Helenius, K., Olson, B. M., Pyzer, A. R., Wang, L. C., Elemento, O., Novak, J., Thornley, T. B., Asara, J. M., Montaser, L., Timmons, J. J., Morgan, T. M., Wang, Y., Levantini, E., … Cantley, L. C. (2017). Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity. Cancer Discovery, 7(7), 750–765. https://doi.org/https://doi.org/10.1158/2159-8290.CD-16-0778
- Plé, P. A., Jung, F., Ashton, S., Hennequin, L., Laine, R., Morgentin, R., Pasquet, G., & Taylor, S. (2012). Discovery of AZD2932, a new quinazoline ether inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorganic & Medicinal Chemistry Letters, 22(1), 262–266.https://doi.org/https://doi.org/10.1016/j.bmcl.2011.11.019
- Pugh, C. W., & Ratcliffe, P. J. (2003). Regulation of angiogenesis by hypoxia: Role of the HIF system. Nature Medicine, 9(6), 677–684. https://doi.org/https://doi.org/10.1038/nm0603-677
- Rini, B. I. (2007). Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 13(4), 1098–1106. . https://doi.org/https://doi.org/10.1158/1078-0432.CCR-06-1989
- Rydén, L., Linderholm, B., Nielsen, N. H., Emdin, S., Jönsson, P.-E., & Landberg, G. (2003). Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Research and Treatment, 82(3), 147–154.https://doi.org/https://doi.org/10.1023/B:BREA.0000004357.92232.cb
- Sakai, R., Henderson, J. T., O'Bryan, J. P., Elia, A. J., Saxton, T. M., & Pawson, T. (2000). The mammalian ShcB and ShcC phosphotyrosine docking proteins function in the maturation of sensory and sympathetic neurons. Neuron, 28(3), 819–833.https://doi.org/https://doi.org/10.1016/s0896-6273(00)00156-2
- Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (New York, N.Y.), 289(5486), 1938–1942.https://doi.org/https://doi.org/10.1126/science289(5486)1938
- Seto, T., Higashiyama, M., Funai, H., Imamura, F., Uematsu, K., Seki, N., Eguchi, K., Yamanaka, T., & Ichinose, Y. (2006). Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer, 53(1), 91–96. https://doi.org/https://doi.org/10.1016/j.lungcan.2006.02.009
- Shibuya, M. (1995). Role of VEGF-flt receptor system in normal and tumor angiogenesis. In. Advances in Cancer Research, 67, 281–316. Elsevier. https://doi.org/https://doi.org/10.1016/s0065-230x(08)60716-2
- Shibuya, M., & Claesson-Welsh, L. (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Experimental Cell Research, 312(5), 549–560.https://doi.org/https://doi.org/10.1016/j.yexcr.2005.11.012
- Simons, M., Gordon, E., & Claesson-Welsh, L. (2016). Mechanisms and regulation of endothelial VEGF receptor signalling. Nature Reviews. Molecular Cell Biology, 17(10), 611–625. https://doi.org/https://doi.org/10.1038/nrm.2016.87
- Sun, Q., Zhou, J., Zhang, Z., Guo, M., Liang, J., Zhou, F., Long, J., Zhang, W., Yin, F., Cai, H., Yang, H., Zhang, W., Gu, Y., Ni, L., Sai, Y., Cui, Y., Zhang, M., Hong, M., Sun, J., … Ren, Y. (2014). Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biology & Therapy, 15(12), 1635–1645.https://doi.org/https://doi.org/10.4161/15384047.2014.964087
- Takahashi, H., & Shibuya, M. (2005). The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clinical Science (London, England : 1979), 109(3), 227–241. https://doi.org/https://doi.org/10.1042/CS20040370
- Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Jones, C. M., Marshall, C. J., Springer, C. J., Barford, D., & Marais, R., Cancer Genome Project (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 116(6), 855–867. https://doi.org/https://doi.org/10.1016/S0092-8674(04)00215-6
- Wang, Y.-J., Kathawala, R. J., Zhang, Y.-K., Patel, A., Kumar, P., Shukla, S., Fung, K. L., Ambudkar, S. V., Talele, T. T., & Chen, Z.-S. (2014). Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochemical Pharmacology, 90(4), 367–378.https://doi.org/https://doi.org/10.1016/j.bcp.2014.06.006
- Warner, A. J., Lopez-Dee, J., Knight, E. L., Feramisco, J. R., & Prigent, S. A. (2000). The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells. Biochemical Journal, 347(2), 501–509. https://doi.org/https://doi.org/10.1042/0264-6021:3470501
- Wedge, S. R., Ogilvie, D. J., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., … Musgrove, H. L. (2002). ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Research, 62(16), 4645–4655.
- Woo, H. Y., & Heo, J. (2012). Sorafenib in liver cancer. Expert Opinion on Pharmacotherapy, 13(7), 1059–1067.https://doi.org/https://doi.org/10.1517/14656566.2012.679930
- Xia, G., Kumar, S. R., Hawes, D., Cai, J., Hassanieh, L., Groshen, S., Zhu, S., Masood, R., Quinn, D. I., Broek, D., Stein, J. P., & Gill, P. S. (2006). Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. Journal of Urology, 175(4), 1245–1252. https://doi.org/https://doi.org/10.1016/S0022-5347(05)00736-6 https://doi.org/https://doi.org/10.1016/S0022-5347(05)00736-6
- Zeng, H., Sanyal, S., & Mukhopadhyay, D. (2001). Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. The Journal of Biological Chemistry, 276(35), 32714–32719.https://doi.org/https://doi.org/10.1074/jbc.M103130200
- Zhang, Y., Chen, Y., Zhang, D., Wang, L., Lu, T., & Jiao, Y. (2018). Discovery of novel potent VEGFR-2 inhibitors exerting significant antiproliferative activity against cancer cell lines. Journal of Medicinal Chemistry, 61(1), 140–157. https://doi.org/https://doi.org/10.1021/acs.jmedchem.7b01091
- Zhang, L., Shan, Y., Ji, X., Zhu, M., Li, C., Sun, Y., Si, R., Pan, X., Wang, J., Ma, W., Dai, B., Wang, B., & Zhang, J. (2017). Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents. Oncotarget, 8(62), 104745–1018632. /oncotarget.20065 https://doi.org/https://doi.org/10.18632/oncotarget.20065
- Zhang, J., Yang, P. L., & Gray, N. S. (2009). Targeting cancer with small molecule kinase inhibitors. Nature Reviews. Cancer, 9(1), 28–39. https://doi.org/https://doi.org/10.1038/nrc2559
- Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., & Gray, N. S. (2014). Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chemical Biology, 9(6), 1230–1241. https://doi.org/https://doi.org/10.1021/cb500129t
- Zuccotto, F., Ardini, E., Casale, E., & Angiolini, M. (2010). Through the “gatekeeper door”: exploiting the active kinase conformation. Journal of Medicinal Chemistry, 53(7), 2681–2694. https://doi.org/https://doi.org/10.1021/jm901443h